Saudi SFDA AR Concentration: 1,608 ARs, 35% in 20 Hands, 13,700 Expiry Cliff

Executive Summary

Saudi Arabia's Saudi Food and Drug Authority (SFDA) requires every foreign medical device manufacturer to appoint an Authorized Representative (AR) — a local entity that holds the Medical Device Marketing Authorization (MDMA) and serves as the regulatory liaison between the manufacturer and the SFDA. The AR holds the MDMA certificate, manages post-market obligations, and is legally responsible for ensuring compliance within the Kingdom.

Our analysis of the SFDA device database (extracted 5 June 2026, 56,737 device listings) reveals a market with 1,608 authorized representatives but striking concentration: the top 20 ARs control 35.4% of all device listings, while 372 ARs (23.1%) hold only a single device. Perhaps most critically, 13,717 devices (24.2% of the database) have MDMA certificates expiring in 2026 or 2027, creating a near-term renewal cliff that will demand significant regulatory capacity from both ARs and manufacturers.

This article quantifies the AR landscape, maps the expiry-risk clusters, and offers practical guidance for manufacturers evaluating AR selection and renewal timing.

Data Source and Method

• Source: Saudi SFDA public device register (partial extract of the MDMA database)
• Analysis sample: SFDA device-register extract dated 5 June 2026 (56,737 device rows after filtering)
• Official public total: SFDA reports 163,711 authorized devices; this partial extract covers 56,420 rows (approximately 34.5% of the total register)
• Analysis date: 6 June 2026
• Computed using: MedDeviceGuide analysis of the SFDA public extract
• Limitations: The extract represents a subset of the full SFDA database. Concentration patterns and expiry distributions are representative of the extract but may not fully reflect the complete register.

Classification Landscape at a Glance

The IVD segment dominates at 28.6% (16,212 devices), reflecting Saudi Arabia's heavy investment in diagnostic infrastructure. Higher-risk Class IIb and III devices together represent 24.0% of listings, underscoring the importance of robust AR post-market surveillance capabilities.

By product category, medical devices account for 68.3% of listings (38,744), while chemicals (often reagents and IVD consumables) represent 31.8% (18,023), and dedicated IVD products 1.2% (653).

Authorized Representative Concentration

The SFDA database lists 1,608 unique authorized representatives managing the 56,737 devices in our extract. However, the distribution is far from even.

Portfolio Size Distribution

Nearly half (48.8%) of all ARs manage 5 or fewer devices, while just 18 ARs (1.1%) each manage more than 500 devices. This "barbell" structure — many small single-product ARs alongside a handful of high-volume operators — is a defining feature of the Saudi market.

Top 20 Authorized Representatives

Top 20 cumulative: 20,092 devices (35.4% of the database)

A notable pattern emerges: some top-volume ARs represent very few manufacturers (e.g., ARL-2019-MD-3382 holds 1,497 devices from just 1 manufacturer, and ARL-2019-MD-9354 holds 1,089 from 1 manufacturer), while others serve as multi-manufacturer hubs. ARs like ARL-2019-MD-2819 (33 manufacturers), ARL-2019-MD-3302 (28 manufacturers), and ARL-2019-MD-3308 (27 manufacturers) function as broad-service gateways for many overseas companies.

The ARs representing a single manufacturer with hundreds of listings are likely captive entities — either wholly owned subsidiaries or exclusive distributors. These are structurally different from the multi-client ARs that operate as commercial regulatory service providers.

The 2026-2027 Expiry Cliff

Perhaps the most operationally significant finding is the expiry-risk distribution. SFDA MDMA certificates have defined validity periods, and our analysis reveals a concentration of expiries in the near term.

Expiry Year Distribution

13,717 devices (24.2%) are set to expire in 2026 or 2027. The 2027 expiry cluster is particularly striking — 10,850 devices, the single largest expiry year in the database. This suggests that a large cohort of MDMA certificates were issued or renewed around 2022-2024 (SFDA MDMA validity is typically 3 years), creating a synchronized renewal wave.

ARs Most Exposed to the Expiry Cliff

Several ARs face acute renewal pressure: ARL-2019-MD-3259 has 96.5% of its 695 devices expiring in 2026-2027, and ARL-2019-MD-9354 has 820 of 1,089 devices (75.3%) facing near-term expiry. For manufacturers working with these ARs, early renewal planning is critical — a sudden surge in renewal volume could strain AR capacity and create processing bottlenecks.

Top Manufacturers in the Saudi Market

The database reveals the following top manufacturers by device listing volume:

Diagnostics companies dominate: Roche, Abbott (two entities combined: 1,776 devices), and Siemens together hold over 8.5% of all listings. The dental and surgical implant segment is also well represented (Straumann, Aesculap, KLS Martin).

Practical Implications for Manufacturers

1. AR Due Diligence Is Non-Negotiable

With 372 ARs holding only a single device, a significant portion of the AR market consists of small, potentially under-resourced operations. For Class IIb and III devices — which require robust post-market surveillance and vigilance reporting — choosing an AR with demonstrated capacity, established SFDA relationships, and adequate staffing is essential. The SFDA's own licensing requirements (MDS-REQ-002) mandate quality management systems for medical device establishments, but enforcement capacity varies.

2. Plan Renewals 12-18 Months Ahead

The 2027 expiry cliff affects 10,850 devices. Manufacturers with MDMA certificates expiring in 2027 should begin renewal preparation no later than Q3 2026. The renewal process requires updated technical documentation, conformity evidence, and post-market surveillance reports — all of which need coordination between the manufacturer and the AR through the SFDA's GHAD electronic system.

3. Evaluate Multi-Manufacturer ARs for Portfolio Efficiency

ARs like ARL-2019-MD-2819 (33 manufacturers) and ARL-2019-MD-3302 (28 manufacturers) have demonstrated the ability to manage diverse portfolios at scale. For manufacturers with multiple product lines or those planning expansion in the Kingdom, these hub-type ARs may offer better economies of scale and regulatory process maturity.

4. Consider the AR Transfer Option for Underperformers

SFDA regulations (under the Law of Medical Devices and its Executive Regulations) allow manufacturers to transfer their MDMA listings to a new AR through the GHAD system. As documented in our Saudi SFDA MDMA AR Transfer Playbook, the SFDA can process transfers even without the outgoing AR's consent in certain circumstances. Manufacturers experiencing poor service from their current AR should not assume they are locked in.

5. The IVD Segment Deserves Special Attention

With IVD-related devices (General IVD, Annex II List A/B) comprising approximately 31% of listings, the IVD regulatory pathway through SFDA is the single largest segment. IVD manufacturers should verify that their AR has experience with the IVD-specific MDMA requirements, including performance evaluation documentation and reference laboratory arrangements where applicable.

Context and Regulatory Framework

Saudi Arabia's medical device regulatory framework is governed by the Law of Medical Devices and implemented through SFDA requirements including MDS-REQ (establishment licensing), MDS-REQ 10 (quality management systems, updated 2026), and the MDMA application process. Foreign manufacturers must appoint an AR, who holds the MDMA certificate and manages all regulatory interactions with the SFDA.

The SFDA has been actively modernizing its regulatory infrastructure as part of Saudi Vision 2030, with increased digitization through the GHAD system, updated classification rules, and enhanced post-market surveillance requirements. The 2026 regulatory updates under MDS-REQ 10 introduce more comprehensive quality management system requirements for licensed establishments, including ARs.

Summary

The Saudi AR market is large but concentrated, with significant near-term expiry risk. Manufacturers entering or maintaining presence in the Kingdom should select ARs based on demonstrated capacity, plan renewals early for the 2027 cliff, and understand the AR transfer mechanism as a safeguard against underperformance.